Editor's PickMarket News

Co-Diagnostics appoints long-time executive Brian Brown as its new chief financial officer

Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday the appointment of Brian Brown as the company’s new chief financial officer (CFO). The company said Brown’s previous experience includes CFO, vice president of accounting and investor relations, and director of finance roles for public and private companies.  In a statement, Brown called Co-Diagnostics a “true success story,” adding that “I was immediately drawn to the Company’s vision and ability to run a profitable, well-managed operation during a period of dynamic growth. I look forward to bringing my experience to support the Company in these endeavors.” The Utah-based company also said it has elevated Dr Jesse Montgomery to the post of chief scientific officer. Dr Montgomery has been the company’s senior vice president of biochemistry, following a career that has included research and bioinformatics positions. READ: Co-Diagnostics completes FDA submission for Emergency Use Authorization for its Logix Smart SARS-CoV-2 DS (Direct Saliva) test In addition, the company said that former CFO Reed Benson will remain with it as general counsel, and Dr Brent Satterfield, founder and former CSO, will continue his involvement with Co-Diagnostics as head of the scientific advisory board. “It has been my pleasure to serve as CSO for Co-Diagnostics,” said Dr Satterfield. “In my new capacity as Head of the Scientific Advisory Board, I look forward to exploring new, innovative ways to further strengthen our scientific base, and advancing our ongoing goal of meeting global health challenges by providing affordable, state-of-the-art diagnostic solutions to the world community.” Dr Montgomery added: “Our Company vision, technology platform, and experience are some of our greatest assets, which combined with the groundwork laid by Dr. Satterfield’s vision have all primed the Company for success. I am excited to oversee the Company’s current and future scientific endeavors as Co-Diagnostics continues to progress and innovate in the field of molecular diagnostics.” The personnel changes follow significant growth Bu Co-Diagnostics in the past year and as the company anticipates additional growth going forward.  Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable.Stay informed and entertained, for free.Subscribe to our newsletter












Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!